---
title: "CSPC Pharma expects H1 profit attributable to owners at RMB 5.9 billion-RMB 6.2 billion"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293909413.md"
description: "CSPC Pharma forecasts H1 2026 profit attributable to owners of RMB 5.9-6.2 billion, up from RMB 2.55 billion. This includes recognizing USD 840 million (approx. RMB 5.74 billion) as license fee income from an AstraZeneca upfront payment. Excluding this income, finished drug sales revenue rose about 10% year-over-year. Interim results will be released on August 20, 2026."
datetime: "2026-07-27T09:32:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293909413.md)
  - [en](https://longbridge.com/en/news/293909413.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293909413.md)
generator: "portal-rs"
---

# CSPC Pharma expects H1 profit attributable to owners at RMB 5.9 billion-RMB 6.2 billion

-   Forecasts profit attributable to owners of RMB 5.9-6.2 billion for the six months ended June 30, 2026, up from about RMB 2.55 billion. \* Expects to recognize USD 840 million of a USD 1.2 billion AstraZeneca upfront payment as Q2 2026 license fee income, about RMB 5.74 billion. \* Finished drugs sales revenue rose about 10% year over year in the period, excluding the license fee income impact. \* Interim results for the period are scheduled for release on Aug. 20, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CSPC Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260727-12257417), on July 27, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [01093.HK](https://longbridge.com/en/quote/01093.HK.md)
- [AZN.US](https://longbridge.com/en/quote/AZN.US.md)
- [AZN.UK](https://longbridge.com/en/quote/AZN.UK.md)
- [00388.HK](https://longbridge.com/en/quote/00388.HK.md)
- [80388.HK](https://longbridge.com/en/quote/80388.HK.md)
- [HKXCY.US](https://longbridge.com/en/quote/HKXCY.US.md)

## Related News & Research

- [CSPC Pharma FY26 H1 profit attributable to shareholders more than doubled to RMB 6.09 billion; revenue rises 40.1% to RMB 18.59 billion](https://longbridge.com/en/news/296433558.md)
- [CSPC Pharma says FDA grants Fast Track status to SYS6090 for MSS/pMMR metastatic colorectal cancer](https://longbridge.com/en/news/297024431.md)
- [M Stanley Raises CSPC PHARMA  TP to HKD12, Rating Overweight](https://longbridge.com/en/news/296557755.md)
- [CSPC PHARMA  1H26 Net Profit Surges Nearly 1.4x, Interim DPS Up 28.6% to HKD0.18](https://longbridge.com/en/news/296435690.md)
- [CSPC says FDA clears RSV vaccine candidate SYS 6057 for US clinical trial](https://longbridge.com/en/news/296903628.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**